Legend Biotech Corporatio... (LEGN)
| Bid | 31.1 |
| Market Cap | 2.95B |
| Revenue (ttm) | 627.24M |
| Net Income (ttm) | -177.03M |
| EPS (ttm) | -0.96 |
| PE Ratio (ttm) | -33.41 |
| Forward PE | -48.09 |
| Analyst | Buy |
| Ask | 33 |
| Volume | 1,123,492 |
| Avg. Volume (20D) | 1,229,160 |
| Open | 32.69 |
| Previous Close | 32.00 |
| Day's Range | 31.82 - 32.85 |
| 52-Week Range | 29.27 - 60.87 |
| Beta | 0.21 |
About LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refr...
Analyst Forecast
According to 12 analyst ratings, the average rating for LEGN stock is "Buy." The 12-month stock price forecast is $80, which is an increase of 149.42% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call TranscriptLegend Biotech Corporation (NASDAQ:LEGN ) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim...